64 results about "Coxsackievirus A" patented technology

An indirect immunofluorescence assay typing kit for coxsackievirus, comprising: a first reagent comprising a mixture of an anti-coxsackievirus A2 polyclonal antibody, an anti-coxsackievirus A4 polyclonal antibody, an anti-coxsackievirus A5 polyclonal antibody, an anti-coxsackievirus A6 polyclonal antibody, and an anti-coxsackievirus A10 polyclonal antibody; a second reagent comprising the anti-coxsackievirus A2 polyclonal antibody; a third reagent comprising the anti-coxsackievirus A4 polyclonal antibody; a fourth reagent comprising the anti-coxsackievirus A5 polyclonal antibody; a fifth reagent comprising the anti-coxsackievirus A6 polyclonal antibody; a sixth reagent comprising the anti-coxsackievirus A10 polyclonal antibody; and a seventh reagent comprising a secondary antibody labeled with a fluorescence compound, wherein the secondary antibody is used for detecting the antibody anti-coxsackieviruses A2, A4, A5, A6 and A10 polyclonal antibodies and a titer of the anti-coxsackieviruses A2, A4, A5, A6 or A10 polyclonal antibody is about 1:5000-151:70000.

The invention discloses a univalent and bivalent inactivated vaccine for preventing Enterovirus 71 (EV71) and Coxsackie virus A16 (Cox.A16) of hand-foot-and-mouth disease, and a preparation method thereof. The preparation method comprises the following steps: screening vaccine strains for the hand-foot-and-mouth disease; establishing and verifying a vaccine strain third-stage seed lot library; culturing cells; inoculating and propagating virus; collecting virus suspension; inactivating the virus; ultra-filtering, concentrating and purifying the virus suspension to obtain vaccine stock solution; and finally preparing the univalent and bivalent inactivated vaccine. The univalent and bivalent inactivated vaccine has good application prospect for preventing the hand-foot-and-mouth disease.

The invention provides a three-color fluorescent RT-PCR (Reverse Transcription-Polymerase Chain Reaction) combined detection method of enterovirus 71, Coxsackie virus A16 and other subtypes of enterovirus as well as a kit thereof. The method can rapidly and accurately detect the enterovirus 71, the Coxsackie virus A16 and the other subtypes of nucleic acids of enterovirus in a sample. The method comprises the following steps of: (1) acquiring and conveying a sample of an infected patient or a suspected patient; (2) preprocessing the sample and extracting RNA; (3) detecting the sample by adopting a one-step PCR-three-color fluorescent probe in-vitro amplification method; and (4) analyzing the corresponding sample according to the fluorescence intensity of each amplification reaction after the amplification reaction is finished, thereby judging the existence of the enterovirus 71, the Coxsackie virus A16 and the other subtypes of nucleic acids of the enterovirus in the acquired sample and being capable of carrying out accurate quantitation (a figure 3) on the enterovirus 71, the Coxsackie virus A16 and the other subtypes of nucleic acids of the enterovirus. The invention realizes the aim of carrying out rapid and accurate combined detection of the enterovirus 71, the Coxsackie virus A16 and the other subtypes of nucleic acids of the enterovirus.

A modified coxsackievirus showing improved safety and/or aggressiveness to be used for oncolytic virotherapy is provided. A modified coxsackievirus showing tissue-specific suppression of proliferation and comprising a imitated genome consisting of the genome of coxsackievirus B3 wild-type (CVB3-WT) inserted with at least one polynucleotide consisting of a target sequence of tissue-specific microR NA (miRNA) is provided. The mutated genome is preferably further inserted with the region encoding GM-CSF in an expressible form.

The invention discloses a preparation method for a recombinant coxsackie virus A16 like particle, which comprises the following steps: (1) cloning a P1 gene and a 3CD gene of a coxsackie virus A16 to a target plasmid to obtain a recombinant expression vector; (2) transforming a target yeast cell by using the recombinant expression vector obtained in the step (1) to obtain a recombinant yeast cellfor expressing the P1 gene and the 3CD gene; and (3) cracking the recombinant yeast cell obtained in the step (2), and separating to obtain the recombinant coxsackie virus A16 like particle. The recombinant coxsackie virus A16 like particle can be prepared in a yeast expression system by the method provided by the invention. Compared with a wild-type P1 gene and a wild-type 3CD gene, the yield ofthe coxsackie virus A16 like particle in the yeast expression system is greatly increased through the optimization of codons of the P1 gene and the 3CD gene, and the recombinant coxsackie virus A16 like particle can be further used for producing candidate preventive vaccines and pharmaceutical compositions for infant hand-foot-and-mouth diseases.

The invention provides a Coxsackie virus A16 virus strain, uses of the strain, a vaccine and a preparation method of the vaccine. The preservation number of the Coxsackie virus A16 virus strain is CGMCC No.6954. The CA16 virus strain has strong virulence, can be used for evaluating the CA16 vaccine, and can also be used for researching the CA16 virus infection mechanism. A method for establishing a Coxsackie virus A16 infected animal model provided by the invention can provide a stable animal model, and provides a foundation for the development of the Coxsackie virus A16 vaccine, the screening of antiviral drugs and the researches of the CA16 virus infection mechanism. The vaccine prepared by using the CA16 virus has effective immune activity.

The invention discloses a coxsackievirus A6 type infected animal model as well as a preparation method and an application thereof. The preparation method of the coxsackievirus A6 type infected animal model provided by the invention comprises a step of infecting an animal with an inactivated coxsackievirus A6 type strain, so that the coxsackievirus A6 type infected animal model is obtained, wherein the coxsackievirus A6 type strain is preserved in China General Microbiological Culture Collection Center with preservation number of CGMCC No.13393. The coxsackievirus A6 type infected animal model, which is stable and is good in repeatability, is constructed on the basis of the CVA6 strain WF057R; and with the application of the model, a research tool is provided for next medicine antiviral therapy and assessment of an immune protective effect of an inactivated viral vaccine.

The invention provides a novel human embryo lung diploid fibroblast strain Walvax-2, CCTCCC201055. The cell strain is sensitive to main epidemic disease viral strains-coxsackievirus 16-type COX.A16 in a group A and enterovirus 71-type EV71 second-strain virus of a hand-foot-mouth disease, and virus output is high. The invention further provides a method for preparing a divalent hand-foot-mouth virus inactivated vaccine and application of the human embryo lung diploid fibroblast strain in preparation of the hand-foot-mouth virus inactivated vaccine. The divalent inactivated vaccine produced by the human embryo lung diploid fibroblast strain can effectively prevent hand-foot-mouth disease.

The present invention provides yeast-expressed Coxsackievirus A10 virus-like particles and applications thereof. According to the present invention, specifically the gene sequences of the P1 protein and the 3CD protein of Coxsackievirus A10 are transformed into yeast cells, and expression is performed to obtain the novel Coxsackievirus A10 virus-like particles; and the yeast-expressed Coxsackievirus A10 virus-like particles have characteristics of high expression, strong immunogenicity and good specificity.

The embodiment of the invention discloses a nucleic acid fluorescence PCR detection kit for a universal enterovirus, a coxsackievirus A16 and an enterovirus 71. The nucleic acid fluorescence PCR detection kit comprises an RNA extracting solution, an RNA eluant, internal standards, a PCR reaction solution, an EV/CA16/EV71 enzyme mixed solution, EV/CA16/EV71 positive reference substances and EV/CA16/EV71 negative reference substances. According to the kit, the universal enterovirus, the coxsackievirus A16 and the enterovirus 71 can be simultaneously detected in a same sample, but other pathogen RNA cannot be detected, the detection sensitivity can reach 400 copie/ml, the detection range is 4.0 E+02-4.0E+08 copies/ml, and a reliable experimental evidence is supplied to early diagnosis on infection of the universal enterovirus, the coxsackievirus A16 and the enterovirus 71.

The invention discloses a CV-A10 virus species and an inactivated vaccine thereof for human. The classification name of the species is coxsackie virus A group 10-type with the preservation number being CGMCC No.16218; and the prepared CV-A10 inactivated vaccine for human consists of 100 [mu]g/ml of CV-A10 inactivated purified antigens and 1mg/ml of aluminium hydroxide. Results indicate that the vaccine products have favorable immunogen and safety.

The invention discloses a kit for detecting coxsackie virus A16-type nucleic acid and a detection method thereof. The kit comprises PCR reaction enzyme, PCR reaction liquid, a negative quality control product and a positive quality control product, wherein the PCR reaction enzyme contains a hot start Taq enzyme, a MLV reverse transcriptase and a RNA enzyme inhibitor; the PCR reaction liquid contains DEPC treating water, dNTPs, 10*PCR Buffer, a coxsackie virus A16-type forward primer, a coxsackie virus A16-type reverse primer and a coxsackie virus A16-type probe, the sequence of the coxsackie virus A16-type forward primer is 5'-CGCTGCCGATACTGAAGCACCG-3', the sequence of the coxsackie virus A16-type reverse primer is 5'-CTGTCTCCGCGGCTTGTAG-3', the sequence of the coxsackie virus A16-type probe is 5'-ACAGATTAGGCACTGGTGTTGTACCGTA-3'; the negative quality control product is the DEPC treating water; and the positive quality control product is the prepared transcription in vitro RNA standard product. The method for fast detecting the sequence of the coxsackie virus A16-type nucleic acid by using a real-time fluorescence quantitative PCR technology has the advantages of specificity, sensitiveness, high speed as well as simple and convenient operation.

The invention belongs to biological field, and relates to a reagent kit for detecting main pathogen Coxsackievirus A16 (Cox A16) and enterovirus 71 of hand-foot-mouth disease, construction method and uses thereof. The reagent kit comprises reaction solutions for detecting four primers of Coxsackievirus A16 and four primers of enterovirus 71.As detected, the reagent kit has a good performance of specificity, sensitivity, rapid amplification, high efficiency and simple identification. The detection system of the invention can detect Coxsackievirus A16 and enterovirus 71 quickly, conveniently, high-effectively, high-specifically and highly-sensitive under temperature of 64 DEG C without need of complicated instruments, which can preferably satisfy clinical detection for hand-foot-mouth disease and be easily popularized in large scope.

The invention belongs to the technical field of biology, and particularly relates to a real-time fluorescence quantification reverse transcription PRC test kit for a rapid coxsackie virus A6 and a test method. The test kit for coxsackie virus A6 nucleic acid comprises a coxsackie virus A6 forward primer shown by a nucleotide sequence such as SEQ ID NO.1, a reverse primer shown by a nucleotide sequence such as SEQ ID NO.2 and a special fluorescence probe shown by a nucleotide sequence such as SEQ ID No.3. The test kit for the coxsackie virus A6 nucleic acid is high in sensitivity, strong in specificity, rapid, easy and convenient to operate, precise and stable in result and wide in application range, and suitable for screening of a coxsackie virus A6 crowd.

The invention relates to new application of luteolin, in particular to application of luteolin in preparing medicine for preventing and treating hand-foot-mouth diseases, particularly, medicine used for resisting enterovirus 71 and/or coxsackievirus A16.

The invention discloses a method for detecting a neutralizing antibody in coxsackievirus A6 (CV-A6), and a recombinant virus applied in the method. According to the method, the neutralizing antibody is detected by using a pseudovirus system packaged by two types of recombinant plasmids; by adopting a single-cycle infected pseudovirus, the safety problem caused by use of live viruses is avoided. The results of a plurality of tests prove that the pseudovirus detection system is a CV-A6 neutralizing antibody detection method which is safe, sensitive, rapid, specific, simple and convenient, and low in cost. Based on the characteristics, the pseudovirus detection system is very suitable for the tests for rapid and large-scale detection of the neutralizing antibody, and has an import applicationvalue for development of a CV-A6 viral vaccine and detection of CV-A6 specific neutralizing antibody level of patients and populations.

The present invention discloses one kind of immune globulin and its preparation and application. The immune globulin is type-70 enterovirus resisting and type-A24 Coxsachie virus resisting chicken yolk immune globulin and is prepared into product with antibody activity. The refined effective component has high purity and high activity, and is ideal product for eye drop and eye ointment. The immune globulin is used in preparing medicine for preventing and treating acute haemorrhagic conjunctivitis caused by type-70 enterovirus and type-A24 Coxsachie virus infection, and the medicine has high specificity, high curative rate and effect superior to conventional medicine.

The invention relates to preparation and application of an anti-Coxsackie virus A16 (CA16) monoclonal antibody. The invention reveals a mouse source anti-CA16 monoclonal antibody, which has good binding specificity, can be used for sensitive detection of Coxsackie A16 virus, and has strong anti-virus infection capacity.

The invention provides a detection test strip for a coxsackie virus A16 type (CA16) IgM (Immune Globulin M) antibody. According to the detection test strip, a nitrocellulose membrane (NC membrane) is coated by a CA16 gene antigen (VP1) and an anti-mouse IgG; and by combining a tihuman IgM monoclonal antibody labeled by colloidal gold, a CA16 specificity IgM antibody in an infected human speciment is detected by applying a membrane chromatography capture method. The test strip for detection, which is disclosed by the invention, has the advantages of simpleness, convenience, quickness and fastness in operation, no need of special instrument or special training, distinct and easily-distinguished result and easiness for popularization; and the detection test strip is suitable for field detection and early-stage diagnosis and assisting function for CA16 infected diagnosis.

The invention belongs to the technical field of bio-medicines and particularly relates to a Coxsackie virus A6 type and A10 type combined detection kit, which includes a Coxsackie virus A6 type reactant and a Coxsackie virus A10 type reactant. The Coxsackie virus A6 type reactant includes a Coxsackie virus A6 type upstream primer, a Coxsackie virus A6 type downstream primer, and a Coxsackie virusA6 type probe having the structure of: 5'-first fluorescent report group-first base sequence- fluorescence quenching group-3'; the Coxsackie virus A10 type reactant includes a Coxsackie virus A10 typeupstream primer, a Coxsackie virus A10 type downstream primer, and a Coxsackie virus A10 type probe having the structure of: 5'-second fluorescent report group-second base sequence-fluorescence quenching group-3'; wherein the first fluorescent report group is different from the second fluorescent report group.

The embodiment of the invention discloses a nucleic acid fluorescent PCR detection kit for coxsacki evirus A16 and human enter ovirus 71. The nucleic acid fluorescent PCR detection kit comprises the following components: RNA extract solution, RNA eluant, internal standard substance, PCR reaction liquid, CA16/EV 71 enzyme mixed liquid, CA16/EV 71 positive control substance and CA16/EV 71 negative control substance. According to the nucleic acid fluorescent PCR detection kit, two kinds of enteroviruses including the coxsacki evirus A16 and human enter ovirus 71 are simultaneously detected in one sample, other pathogen RNAs can not be detected, and RNAs are extracted by a paramagnetic particle method, so that the detection sensitivity, accuracy and stability are improved, the detection sensitivity achieves 400 copie/ml, the detection range is (4.0E+02)-(4.0E+08) copies/ml, and reliabile experimental evidences are provided for early diagnosis of the infection of the coxsacki evirus A16 and the human enter ovirus 71.